Table 1.
Baseline demographic, clinical, and biochemical characteristics of ESRD patients
| Parameter | Multiple dose (100 mg t.i.d.) |
||
|---|---|---|---|
| Before meal (n = 9) | After meal (n = 10) | Total (n = 19) | |
| Demographic and clinical characteristics | |||
| Age, yr | |||
| Mean ± SD | 60.7 ± 10.0 | 62.2 ± 8.9 | 61.5 ± 9.2 |
| Range | 47–73 | 44–73 | 44–73 |
| Sex, male, n (%) | 4 (44.4) | 5 (50.0) | 9 (47.4) |
| Primary CKD disease | |||
| Chronic glomerulonephritis | 4 (44.4) | 4 (40.0) | 8 (42.1) |
| Diabetic nephropathy | 2 (22.2) | 4 (40.0) | 6 (31.6) |
| Chronic pyelonephritis | 0 | 0 | 0 |
| Polycystic kidney disease | 2 (22.2) | 0 | 2 (10.5) |
| Nephrosclerosis | 0 | 1 (10.0) | 1 (5.3) |
| Other | 1 (11.1) | 1 (10.0) | 1 (10.5) |
| Before meal (n = 8) | After meal (n = 9) | Total (n = 17) | |
|---|---|---|---|
| Biochemical pharmacodynamic parameters | |||
| Serum phosphate at day 1 (mg/dl) | 8.33 ± 1.34 | 7.69 ± 1.27 | 7.99 ± 1.31 |
| Corrected serum Ca at day 1 (mg/dl) | 8.85 ± 0.84 | 8.72 ± 0.71 | 8.78 ± 0.75 |
| Serum intact PTH at day 1 (pg/ml) | 323.1±132.7 | 373.7 ± 205.1 | 349.9 ± 171.5 |
| Median | 304.0 | 441.0 | 321.0 |
| Serum FGF23 at day 1 (pg/ml) | 22,828 ± 29,562 | 15,180 ± 12,073 | 18,779 ± 21,695 |
| Median | 9870.00 | 17,200.00 | 12,100.00 |
Data are presented as n (%) unless otherwise indicated.
Ca, calcium; ESRD, end-stage renal disease; FGF23, fibroblast growth factor−23; PTH, parathyroid hormone; t.i.d., 3 times daily.